Glaukos Corp
Manufacturing · California, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
1 Glaukos Way, Aliso Viejo, California, ...Phone Number
(949) 367-9600Website
www.glaukos.comRevenue
$551.3 MillionStock Symbol
GKOSIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
5
1
1
1
1
1
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Explore more
Glaukos Corp Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Glaukos Corp your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Glaukos Corp
Click to see if Glaukos Corp had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Glaukos Corp has new funding data
Check out if Glaukos Corp is spiking on competitors!
Check if Glaukos Corp has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Glaukos Corp recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Glaukos Corp, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Glaukos Corp launches new products
Recommended Actions
Reach out to Masked Content who joined Glaukos Corp as Masked Content
Find 2 more new buyers
Compare Similar Companies to Glaukos Corp
Compare insights from companies similar to Glaukos Corp, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Glaukos Corp
$551.3M
1K - 5K
Public
$187.3M
1998
AT
Alexander ThurmanSenior Vice President & Chief Financial Officer
$408.5M
1K - 5K
Private
$921.8M
2006
SR
Shana RossSenior Vice President and Chief Human Resources Officer
Company Profile Activity
Activity Insights
Glaukos Corp is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Glaukos Corp is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Glaukos Corp.
Glaukos Corp financials insights
Gather financial insights about Glaukos Corp, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2002
Series A
$10M
2008
Series D
$35M
2013
Series F
$30M
2015
Stock Offering
$112.3M
Glaukos Corp Tech Stack
A closer look at the technologies used by Glaukos Corp
See more technologies
Most Recent Scoops
Project
Glaukos Corp has acknowledged that commercial payer denials and appeals are expected to be a feature of the early Epioxa launch period, given that keratoconus is predominantly a commercially insured patient population unlike the Medicare-focused IDOS. The company's goal is to optimize the denials and appeals process through the second and third quarters, targeting a strong commercial payer position heading into the following year.
Accounting, Billing & Invoice, Finance
Project
Glaukos Corp has announced that the launch of Epioxa, a treatment for keratoconus, is progressing ahead of expectations, with the company deploying a rare disease go-to-market model centered on a focused network of high-volume sites of care supported by a patient hub and access liaisons. This approach marks a strategic shift from the legacy Photrexa model, which had been limited to approximately 10,000 patients annually due to a broad site of care network.
Pharmaceuticals, Corporate Strategy
Project
Glaukos Corp is facing a proposed LCD requirement that would mandate Selective Laser Trabeculoplasty (SLT) as a prerequisite step before patients can access IDOS, which the company argues is clinically inappropriate given that SLT is contraindicated for certain patients based on disease severity, anatomy, prior interventions, and other factors. Glaukos Corp is advocating for clinical carve-outs to the proposed blanket SLT requirement rather than an outright elimination of SLT as a first-line option.
Project
Glaukos Corp has identified Medicare Advantage copay obligations as a financial access barrier for IDOS, noting that while approximately 10 to 15 percent of Medicare Advantage patients have plans with little to no out-of-pocket costs, the majority face copay requirements that the company is legally prohibited from offsetting through copay assistance programs. The company noted that patients who reach the federal out-of-pocket maximum through other procedures earlier in the year may no longer face this barrier by the third or fourth quarter.
Barriers
Project
Medical Administration
Glaukos Corp News & Media
Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript
Glaukos Corporation (GKOS) Q2 2026 Earnings Call July 29, 2026 4:30 PM EDTCompany ParticipantsChristopher Lewis - Vice President of Investor Relations &...Patient enrolment concludes in Glaukos’ Preserflo MicroShunt trial
The pivotal prospective, multi-centre, single-arm study is taking place at sites in the US and Canada.Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?
Disposition represented 19% of insider's equity holdings under pre-established Rule 10b5-1 trading plan. Thurman retains 43,681 shares worth approximately $6.77 million.Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?
Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Glaukos Corp
Sign Up For FreeTo access detailed company insights
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate ope... Read More
